Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 28 of 119 for:    COP1

Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate (ASSERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00203047
Recruitment Status : Terminated (Slow enrollment decreased sample size; No unexpected safety issues.)
First Posted : September 20, 2005
Results First Posted : January 6, 2014
Last Update Posted : January 6, 2014
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries

Brief Summary:
This is a study evaluating the effect on brain volume of daily glatiramer acetate (GA) and add-on pulse steroids.

Condition or disease Intervention/treatment Phase
Relapsing Remitting Multiple Sclerosis Drug: Glatiramer Acetate Drug: Placebo Drug: Prednisone Phase 4

Detailed Description:

One interim analysis was planned for possible early termination due to proven efficacy when 75% of the preplanned 500 (approx. 375 patients) recruited patients completed the entire study duration or early discontinued.

In addition to the stopping rule already given for proven efficacy, the sponsor was also interested in examining the data for futility (i.e., absence of the desired treatment effect) with the view to terminating the trial if an "insufficient" effect of the treatment is seen. The reasons why the need for futility arose were:

  1. Recruitment difficulties
  2. Increasing dropout rate
  3. Budgetary constraints

The primary efficacy measure is defined as the percent change from baseline to termination (Month 36 or Early Termination) in normalized brain volume (Brain Atrophy) measured according to the SIENA (Structural Imaging Evaluation using Normalization of Atrophy) method. However, since not many patients had completed the entire study at the time of futility analysis, it was the sponsor's decision that the futility analysis be performed on patients with MRI scans at months 24 or 36 or at early termination visits - the latest available.

Based on the recalculation of study power (probability is unconditioned on the interim result and provide the real power of the study if designed anew), conditional power (based on the interim results) and risk assessment of a false negative, the Data Monitoring Committee agreed that the study should be terminated early.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 414 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-on Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated With Glatiramer Acetate (GA)
Study Start Date : January 2005
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: GA + Placebo
Glatiramer acetate (GA) 10mg as a subcutaneous injection daily, plus a placebo to mimic prednisone given daily.
Drug: Glatiramer Acetate
20mg glatiramer acetate (GA) administered by daily subcutaneous injections
Other Name: Copaxone

Drug: Placebo
Placebo for prednisone given daily

Experimental: GA + Prednisone
Glatiramer acetate (GA) 20mg daily as a subcutaneous injection, plus 1250 mg of prednisone daily.
Drug: Glatiramer Acetate
20mg glatiramer acetate (GA) administered by daily subcutaneous injections
Other Name: Copaxone

Drug: Prednisone
Prednisone 1250 mg taken daily
Other Name: corticosteroid




Primary Outcome Measures :
  1. Percent Change From Baseline to Termination in Normalized Brain Volume Measured According to the SIENA (Structural Imaging Evaluation Using Normalization of Atrophy) Method [ Time Frame: Day 0, latest scan at month 24, 36 or early termination visit ]

    Results represent the database as of January 29, 2009. Brain volume was measured at baseline and at months 24, 36 and at early termination visits by magnetic resonance imaging (MRI). Brain atrophy was measured by comparing the change in brain volume from baseline to the latest scan at the three during study timeframes. SIENA is a fully automated method of analyzing longitudinal brain change.

    Adjusted (least square) mean values are presented.



Secondary Outcome Measures :
  1. Cumulative Number of Enhancing Lesions at Months 12, 24 and 36 [ Time Frame: Months 12, 24, and 36 ]

    Results represent the database as of January 29, 2009.

    Enhancing lesions are lesions that show inflammation on an MRI and are assumed to be new lesions. The sum of enhancing lesions observed in MRIs taken at months 12, 24 and 36 are offered.


  2. Change From Baseline to Month 36 or Early Termination Visit in Volume of T2-Lesions [ Time Frame: Day 0, Month 36 or the early termination visit ]

    Results represent the database as of January 29, 2009.

    The difference in T2 brain lesion volume as observed in MRIs from baseline to Month 36 or the early termination visit. T2 lesions are hyperintense lesions meaning that they appear as bright spots on the MRI image. These tend to show the total number of lesions and disease burden.


  3. Change From Baseline to Month 36 or Early Termination Visit in Volume of Hypointense Lesions [ Time Frame: Day 0, Month 36 or early termination visit ]

    Results represent the database as of January 29, 2009.

    The difference in hypointense brain lesion volume as observed in MRIs from baseline to Month 36 or the early termination visit. Hypointense lesions display as dark areas on the MRI image, and represent areas of permanent axonal damage.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinically definite multiple sclerosis (CDMS) according to Poser (Ann. Neurol. 1983) or McDonald (Ann. Neurol. 2001)
  2. Subjects eligible for GA treatment based on the investigator's clinical assessment and according to the current indication.
  3. Subjects must have a relapsing remitting disease course.
  4. Subjects must have had at least 1 documented relapse within the last year prior to study entry.
  5. Subjects may be male or female. Women of childbearing potential must practice an acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, double-barrier method (condom or intrauterine device [IUD] with spermicide), or partner's vasectomy.
  6. Subjects must be between the ages of 18 and 55 years inclusive.
  7. Subjects must be ambulatory, with a Kurtzke Expanded Disability Status Scale (EDSS) score between 0 and 5.0 inclusive.
  8. Subjects must be willing and able to give written informed consent prior to entering the study.

Exclusion Criteria:

  1. Long-term glatiramer acetate users who have been on therapy within 6 months of the baseline magnetic resonance imaging (MRI). New glatiramer acetate users who have initiated therapy for more than 6 weeks prior to the baseline MRI.
  2. Previous use of cladribine.
  3. Previous use of mitoxantrone.
  4. Use of digitalis at study entry.
  5. Previous use of immunosuppressive agents (such as azathioprine, cyclophosphamide or mycophenolate mofetil) in the last 6 months prior to screening.
  6. Use of experimental or investigational drugs, including intravenous (IV) immunoglobulin within 6 months prior to screening.
  7. Use of interferon agents within 1 month prior to the baseline MRI.
  8. Use of corticosteroids (IV, intramuscular [IM] and/or by mouth [PO]) within 30 days prior to the baseline MRI.
  9. Chronic corticosteroid (IV, IM and/or PO) treatment (more than 30 consecutive days) in the 6 months prior to the screening visit.
  10. Subjects with diabetes.
  11. Previous total body irradiation or total lymphoid irradiation.
  12. Pregnancy or breast feeding.
  13. Significant medical or psychiatric condition that affects the subject's ability to give informed consent, or to complete the study, or any condition which the investigator feels may interfere with participation in the study (e.g. alcohol or drug abuse).
  14. Other diseases that can cause brain atrophy (ex. neurodegenerative disorder, cerebrovascular disease, history of alcohol abuse).
  15. Bone density less than -2.5 standard deviations (SD) (osteoporosis).
  16. A known history of sensitivity to mannitol.
  17. Contraindication to, or known history of, sensitivity or severe reaction to steroids.
  18. A known history of sensitivity to gadolinium.
  19. Inability to successfully undergo MRI scanning.
  20. Previous use of natalizumab.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00203047


Sponsors and Collaborators
Teva Pharmaceutical Industries
Investigators
Layout table for investigator information
Study Chair: Jean-Louis Stril, MD Teva Neuroscience Canada

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier: NCT00203047     History of Changes
Other Study ID Numbers: TNC GA MS 2004_01
First Posted: September 20, 2005    Key Record Dates
Results First Posted: January 6, 2014
Last Update Posted: January 6, 2014
Last Verified: November 2013
Keywords provided by Teva Pharmaceutical Industries:
Multiple Sclerosis
brain atrophy
Glatiramer Acetate
Copaxone
Steroids
Prednisone
Additional relevant MeSH terms:
Layout table for MeSH terms
Glatiramer Acetate
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Prednisone
(T,G)-A-L
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Adjuvants, Immunologic
Immunologic Factors
Immunosuppressive Agents
Antirheumatic Agents